Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opko Health, Inc. - Common Stock (NQ:OPK)

1.790 -0.020 (-1.10%)
Streaming Delayed Price Updated: 11:11 AM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Opko Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
Via Benzinga
Pfizer - OPKO Health's Growth Hormone Deficiency Candidate Receives FDA Response Letter
The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE) and OPKO Health Inc's (NASDAQ: OPK) somatrogon. Somatrogon... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of... 
Via Benzinga
Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition
Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
Opko Health Posts Data From COVID-19 Trial With Its Kidney Disease Treatment
OPKO Health Inc (NASDAQ: OPK) has announced preliminary topline results from its Phase 2 trial with Rayaldee to treat mild-to-moderate COVID-19. This study... 
Via Benzinga
Bulls Find Silver Lining Into the Close
While it isn't exactly a ringing endorsement that the market is heading higher, it is an indication that the Grinch hasn't entirely spoiled the fun. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Genfit (NASDAQ:GN... 
Via Benzinga
63 Biggest Movers From Friday
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. X4 Pharmaceuticals, Inc... 
Via Benzinga
OPKO Health Q3 Earnings Ahead Of Expectations
OPKO Health Inc (NASDAQ: OPK) reported Q3 revenues were down 10% Y/Y to $385.8 million, beating the consensus of $302.27 million. Revenue from diagnostic services... 
Via Benzinga
Opko Health (OPK) Q3 2021 Earnings Call Transcript
OPK earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ: 
Via Benzinga
This Growth Hormone Drug Could Be a Boost For Pfizer
Pfizer and OPKO Health's human growth hormone drug, somatrogon, could be approved by the U.S. Food and Drug Administration next January. 
Via The Motley Fool
Exposures Product Safety
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers eFFECTOR Therapeutics (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Why Opko Health Shares Shriveled by Nearly 8% on Friday
The coronavirus stock didn't impress with its Q2 results. 
Via The Motley Fool
Exposures COVID-19
Opko Health (OPK) Q2 2021 Earnings Call Transcript
OPK earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news. 
Via The Motley Fool
Analyzing OPKO Health's Unusual Options Activity
OPKO Health (NASDAQ:OPK) shares experienced unusual options activity on Thursday. The stock price moved up to $3.56 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy
OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop,... 
Via Benzinga
OPKO Health, Nicoya Therapeutics Ink Rayaldee Pact For Hyperparathyroidism In Greater China
OPKO Health Inc's (NASDAQ: OPK) subsidiary EirGen Pharma has agreed to develop and commercialize Rayaldee to treat secondary hyperparathyroidism in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021
Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE: 
Via Benzinga
OPKO Health Offloads Fill and Finish Manufacturing Facility in Ireland To Horizon Therapeutics
OPKO Health Inc's (NASDAQ: OPK) subsidiary, EirGen Pharma Ltd, has agreed to sell one of its facilities in Waterford, Ireland, to Horizon Therapeutics plc... 
Via Benzinga
Cramer Shares His Thoughts On MP Materials, Nokia And More In 'Lightning Round'
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would pass on Opko Health Inc. (NASDAQ: OPK). BOSTON OMAHA Corp (NASDAQ: BOMN) is a hard pass, said Cramer... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.